ImmunityBio Inc. experienced a significant increase in its stock price on Tuesday, with shares rising 9.94 percent to close at $9.29 per share. The movement followed a high-profile meeting between company founder Dr. Patrick Soon-Shiong and Turkish President Recep Tayyip Erdogan, which was publicly documented through social media channels. The encounter generated investor enthusiasm regarding the biotechnology firm’s intentions to establish operations in Turkey.
The company’s therapeutic focus centers on Anktiva, an immunotherapy medication approved by the FDA for treating specific forms of non-muscle invasive bladder cancer. The drug has secured regulatory acceptance across 34 countries and regions, including the United States, the United Kingdom, Saudi Arabia, Macau, and various European nations. To support its international expansion strategy, ImmunityBio raised $100 million in funding, comprising $75 million from non-dilutive financing provided by Oberland Capital and $25 million from a debt-to-equity conversion facilitated by Nant Capital LLC.
The company’s financial performance in the second quarter demonstrated substantial growth, with total revenues reaching $51.24 million, representing a 94 percent increase compared to $26.4 million in the equivalent prior-year period. However, net losses expanded to $230.39 million from $92.57 million year-over-year, reflecting elevated operational costs. Institutional investor interest remained elevated during the quarter, with 27 hedge funds holding positions in the stock, up from 25 in the preceding quarter, while their combined holdings increased by 62.6 percent to $314.9 million from $193.7 million.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI